News Sentiment

QNCX sentiment intelligence

Quince Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed

Weighted score 56 Balanced news tone 57 relevant articles

Exchange NASDAQ United States

Sector Healthcare Market context

Industry Biotechnology Read-through group

Latest close 18.88 Week of 17 Jul 2026

Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+7.6% over one week, -0.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Quince Therapeutics updates its strategy as a clinical-stage biotech. QNCX focuses on targeted drug

Market Reaction

Price moving ahead of tone

63/100 confidence

Primary event Market update 75/100 classification

One-week reaction 7.6% Price confirming higher

Trend fit Trend inactive -0.1% over four weeks

Fair value -92.2% Below fair value

Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance

Positive 13

Neutral 41

Negative 3

Relevance

Why the article matched

Direct first

Direct company coverage 49

Industry context 8

Sector context 0

Sources

Coverage mix

Publishers

Stock Titan 10

Market source 7

Investing.com 6

TradingKey 6

Moomoo 4

GlobeNewswire 4

TradingView 4

simplywall.st 3

Event Lens

What the news is about

Classified themes

Market update 23

Earnings 14

Deals and strategy 10

Analyst action 6

Regulatory and legal 2

Guidance 1

Balance sheet 1

Sentiment Trail

Score over time

50 baseline

Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57

Market source Industry context

Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks

Tone: Neutral 50/100
Event: Earnings
Published: 16 Jul 2026 18:49
Source: Market source

Market source Industry context

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone: Neutral 50/100
Event: Earnings
Published: 13 Jul 2026 12:30
Source: Market source

AD HOC NEWS Direct company coverage

Quince Therapeutics updates its strategy as a clinical-stage biotech. QNCX focuses on targeted drug

Quince Therapeutics is a clinical-stage biotechnology company developing precision medicines for serious diseases. The company's strategy involves heavy investment in R&D, focusing on targeted mechanisms of action, and navigating a long regulatory path, typical for small-cap biot

Tone: Neutral 50/100
Event: Regulatory and legal
Published: 07 Jul 2026 16:40
Source: AD HOC NEWS

The National Law Review Direct company coverage

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics, Inc. (Nasdaq: QNCX) has engaged LifeSci Capital as its exclusive financial advisor to explore strategic alternatives for maximizing shareholder value, including potential partnerships, mergers, or acquisitions. LifeSci Capital will also advise on any liabilit

Tone: Neutral 50/100
Event: Deals and strategy
Published: 04 Jul 2026 19:12
Source: The National Law Review

Stock Titan Direct company coverage

Quince Therapeutics recruits top lung doctors for LAM-001 development

Quince Therapeutics (Nasdaq: QNCX) has established a Scientific Advisory Board (SAB) comprising internationally recognized leaders in pulmonary medicine to guide the development of LAM-001. LAM-001 is an inhaled rapamycin targeting serious pulmonary conditions such as PH-ILD, BOS

Tone: Neutral 50/100
Event: Market update
Published: 02 Jul 2026 10:10
Source: Stock Titan

Moomoo Direct company coverage

Press Release: Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

Quince Therapeutics has appointed Dr. Donald C. Tashkin and Dr. Robert J. Kaner to its newly formed Scientific Advisory Board (SAB) to bolster its idiopathic pulmonary fibrosis (IPF) drug discovery program. These distinguished pulmonologists will provide expert guidance on clinic

Tone: Positive 71/100
Event: Guidance
Published: 01 Jul 2026 07:09
Source: Moomoo

GlobeNewswire Direct company coverage

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

Quince Therapeutics has established a Scientific Advisory Board (SAB) comprising leading experts in pulmonary medicine to guide the development of LAM-001, an inhaled rapamycin formulation. This SAB will focus on advancing LAM-001 for various pulmonary indications, including PH-I

Tone: Positive 72/100
Event: Market update
Published: 30 Jun 2026 11:40
Source: GlobeNewswire

TradingView Direct company coverage

Price to earnings forward of Quince Therapeutics, Inc. – NASDAQ:QNCX

This article provides the "Price to earnings forward" metric for Quince Therapeutics, Inc. (NASDAQ: QNCX) sourced from TradingView. It appears to be a financial data snippet rather than a detailed analysis, likely indicating a data point available on the platform for the biotechn

Tone: Neutral 50/100
Event: Earnings
Published: 29 Jun 2026 21:39
Source: TradingView

TradingView Direct company coverage

Enterprise value to revenue forward of Quince Therapeutics, Inc. – NASDAQ:QNCX

This article displays the "Enterprise value to revenue forward" metric for Quince Therapeutics, Inc. (NASDAQ: QNCX) on TradingView. It indicates that for the measured period, the value is not available, showing "No trades" and "Not available." The content is primarily a data plac

Tone: Neutral 50/100
Event: Earnings
Published: 29 Jun 2026 09:11
Source: TradingView

TradingView Direct company coverage

Quince Therapeutics, Inc. Actuals & Estimates (NASDAQ:QNCX)

This article provides an overview of Quince Therapeutics, Inc. (NASDAQ: QNCX), covering its stock performance, financial estimates, and key statistics. It details recent price changes, analyst forecasts with high and low estimates, and historical price data. The report also inclu

Tone: Neutral 50/100
Event: Analyst action
Published: 29 Jun 2026 07:09
Source: TradingView

The Globe and Mail Direct company coverage

Quince Therapeutics Implements 1-for-20 Reverse Stock Split

Quince Therapeutics has implemented a 1-for-20 reverse stock split, effective June 29, 2026, consolidating 20 shares into one and reducing the total outstanding shares to approximately 977,963. Trading on a split-adjusted basis began June 30, 2026, with the company retaining its

Tone: Negative 39/100
Event: Market update
Published: 27 Jun 2026 17:39
Source: The Globe and Mail

Stock Titan Direct company coverage

Quince Therapeutics (QNCX) confirms 1-for-20 reverse split and sharp share reduction

Quince Therapeutics (QNCX) has confirmed a 1-for-20 reverse stock split, reducing its outstanding common shares from 19,559,257 to approximately 977,963. The split, effective June 29, 2026, with split-adjusted trading starting June 30, 2026, will not alter percentage ownership or

Tone: Neutral 50/100
Event: Market update
Published: 26 Jun 2026 20:40
Source: Stock Titan

Stock Titan Direct company coverage

1-for-20 reverse split consolidates Quince Therapeutics (NASDAQ: QNCX) shares

Quince Therapeutics (NASDAQ: QNCX) has implemented a 1-for-20 reverse stock split, effective 11:59 p.m. Eastern Time on June 29, 2026, with trading on a split-adjusted basis beginning June 30, 2026. This action reduces the number of outstanding shares from approximately 19.56 mil

Tone: Neutral 50/100
Event: Market update
Published: 26 Jun 2026 13:40
Source: Stock Titan

TradingView Direct company coverage

Price to sales forward of Quince Therapeutics, Inc. – NASDAQ:QNCX

This page displays the "Price to sales forward" financial metric for Quince Therapeutics, Inc. (NASDAQ: QNCX). It indicates the value and change over a specific period for this financial ratio. The content is presented by TradingView, a financial platform offering market data and

Tone: Neutral 50/100
Event: Market update
Published: 26 Jun 2026 11:40
Source: TradingView

Investing.com Direct company coverage

Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating

Cantor Fitzgerald has reiterated an Overweight rating on Quince Therapeutics (NASDAQ:QNCX) with a $4.00 price target, following the company's recent reverse merger acquisition of Orphai Therapeutics. Despite high stock volatility and a 97% year-to-date decline, the firm views Qui

Tone: Positive 71/100
Event: Deals and strategy
Published: 25 Jun 2026 14:40
Source: Investing.com

Investing.com Direct company coverage

Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight

Cantor Fitzgerald has reiterated an Overweight rating for Quince Therapeutics Inc. (NASDAQ:QNCX), setting a price target of $4.00 for the combined entity after its reverse merger with Orphai Therapeutics. Despite the company's current low market capitalization and significant sto

Tone: Positive 70/100
Event: Deals and strategy
Published: 25 Jun 2026 13:13
Source: Investing.com

Investing.com Australia Direct company coverage

Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating By Investing.com

Cantor Fitzgerald has reiterated an Overweight rating on Quince Therapeutics (NASDAQ:QNCX) with a $4.00 price target. This follows Quince's acquisition of Orphai Therapeutics through a reverse merger and positive results from a phase 2a study of LAM-001 for pulmonary hypertension

Tone: Positive 63/100
Event: Deals and strategy
Published: 25 Jun 2026 12:13
Source: Investing.com Australia

Moomoo Direct company coverage

$Quince Therapeutics (QNCX.US)$

The article is a brief post from the moomoo Community discussing Quince Therapeutics (QNCX.US). It appears to be a user-generated content focused on the stock. The author, 春夏秋冬冬, commented on the stock on June 25th.

Tone: Neutral 50/100
Event: Market update
Published: 25 Jun 2026 03:40
Source: Moomoo

Moomoo Direct company coverage

Leerink Partners Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4

Leerink Partners has initiated coverage on Quince Therapeutics (QNCX.US) with a Buy rating. The financial firm also set a price target of $4 for the company's stock.

Tone: Positive 87/100
Event: Analyst action
Published: 24 Jun 2026 19:09
Source: Moomoo

marketscreener.com Direct company coverage

Leerink Partners Initiates Quince Therapeutics at Outperform With $4 Price Target

Leerink Partners has initiated coverage on Quince Therapeutics with an Outperform rating and a $4 price target. The biotechnology company, specializing in treatments for rare diseases, is currently trading at approximately $0.97 per share. Analysts' consensus rates QNCX as "Outpe

Tone: Positive 76/100
Event: Analyst action
Published: 24 Jun 2026 11:42
Source: marketscreener.com

Investing.com Direct company coverage

Leerink initiates Quince Therapeutics stock with Outperform rating

Leerink has initiated coverage on Quince Therapeutics Inc. (NASDAQ:QNCX) with an Outperform rating and a $4.00 price target, suggesting substantial upside from its current $0.97 stock price. The valuation comes after Quince's acquisition of Orphai Therapeutics, making it a clinic

Tone: Positive 70/100
Event: Analyst action
Published: 24 Jun 2026 11:42
Source: Investing.com

GuruFocus Direct company coverage

QNCX Initiated Coverage by Cantor Fitzgerald -- Rating Set to Overweight

Cantor Fitzgerald initiated coverage on Quince Therapeutics (QNCX) with an "Overweight" rating and a $4.00 price target. Despite a low GF Score™ of 21/100, indicating potential long-term return challenges, the company's financial strength is rated 7/10. The positive analyst outlo

Tone: Positive 69/100
Event: Analyst action
Published: 23 Jun 2026 18:40
Source: GuruFocus

StocksToTrade Direct company coverage

Quince Therapeutics Inc. (QNCX) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live stock quotes and charts for Quince Therapeutics Inc. (QNCX) on NASDAQ, showing its current price as $0.9879 with a 2.03% increase. It includes a basic price history chart and notes that there are no analyst ratings or earnings information currently availab

Tone: Neutral 50/100
Event: Earnings
Published: 23 Jun 2026 16:42
Source: StocksToTrade

Investing.com Direct company coverage

Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating

Cantor Fitzgerald initiated coverage on Quince Therapeutics Inc. (NASDAQ:QNCX) with an overweight rating and a $4.00 price target. The firm noted Quince's recent reverse merger with Orphai Therapeutics and its focus on pulmonary hypertension treatments, characterizing it as a com

Tone: Positive 80/100
Event: Deals and strategy
Published: 23 Jun 2026 13:42
Source: Investing.com

Moomoo Direct company coverage

Cantor Fitzgerald Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4

Cantor Fitzgerald has initiated coverage on Quince Therapeutics (QNCX.US) with a Buy rating. The firm has set a target price of $4 for the company's stock. This initiation suggests a positive outlook on Quince Therapeutics' future performance.

Tone: Positive 80/100
Event: Analyst action
Published: 23 Jun 2026 10:39
Source: Moomoo